Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 22/11/2020
SIETES contiene 93161 citas

 1 a 20 de 52 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Goldacre B. The WHO joint statement from funders on trials transparency. BMJ 2017;357:j2816. [Ref.ID 101660]
2.Enlace a cita original
Zarin DA, Tse T, Williams RJ, Rajakannan T. Update on trial registration 11 years after the ICMJE policy was established. N Engl J Med 2017;376:381-91. [Ref.ID 101395]
3.Enlace a cita original
Garner P, Hopewell S, Chandler J, MacLehose H, Akl EA, Beyene J, Chang S, Churchill R, Dearness K, Guyatt G, Lefebvre C, Liles B, Marshall R, Martínez García L, Mavergames C, Nasser M, Qaseem A, Sampson M, Soares-Weiser K, Takwoingi Y, Thabane L, Trivella M, Tugwell P, Welsh E, Wilson EC, Schünemann HJ. When and how to update systematic reviews: consensus and checklist. BMJ 2016;354:i3507. [Ref.ID 100641]
4. Cita con resumen
Taichman DB, Backus J, Baethge C, De Leeuw PW, Drazen JM, Fletcher J, Frizelle FA, Groves T, Haileamlak A, James A, Laine C, Peiperl L, Sahni P, Wu S. Sharing clinical trial data — A proposal from the International Committee of Medical Journal Editors. N Engl J Med 2016;374:28 de enero. [Ref.ID 99977]
5.Tiene citas relacionadas Cita con resumen
Goldacre B. Are clinical trial data shared sufficiently today? No. BMJ 2013;347:16-7. [Ref.ID 96129]
6. Cita con resumen
Anónimo. Authorship and accountability. Lancet 2013;382:744. [Ref.ID 95993]
7. Cita con resumen
Bosch X, Hernández C, Pericas JM, Doti P. Ghostwriting policies in high-impact biomedical journals: a cross-sectional study. JAMA Intern Med 2013;173:920-1. [Ref.ID 95514]
8.Tiene citas relacionadas
Doshi P, Jefferson T. The first 2 years of the European Medicines Agency's policy on access to documents: secret no longer. JAMA Intern Med 2013;173:380-2. [Ref.ID 95096]
9.Tiene citas relacionadas Cita con resumen
Steinbrook R. The European Medicines Agency and the brave new world of access to clinical trial data. JAMA Intern Med 2013;173:373-4. [Ref.ID 95095]
11.Tiene citas relacionadas Cita con resumen
Lundh A, Krogsboll LT, Gotzsche PC. Acces to data in industry-sponsored trials. Lancet 2011;378:1995-6. [Ref.ID 91948]
12.Tiene citas relacionadas
Anónimo. What constitutes full access to data in industry-funded trials?. Lancet 2011;378:1976. [Ref.ID 91944]
13. Cita con resumen
Shaw D. The ICMJE's definition of authorship is unethical. BMJ 2011;343:999. [Ref.ID 91823]
14.Enlace a cita original
The PLoS Medicine Editors. Ghoswriting revisited: new perspectives but few solutions in sight. PLOS Medicine 2011;8:e1001084. [Ref.ID 91074]
15.Tiene citas relacionadas Cita con resumen
16.Tiene citas relacionadas Cita con resumen
17.Enlace a cita original
Drazen JM, de Leew PW, Laine C, Mulrow C, DeAngelis CD, Frizelle FA, Godlee F, Haug C, Hébert PC, James A, Kotzin S, Marusic A, Reyes H, Rosenberg J, Sahni P, Van Der Weyden MB, Zhaori G. Toward more uniform conflict disclosures. JAMA 2010;304:212-3. [Ref.ID 88958]
Drazen JM, De Leeuw PW, Laine C, Mulrow C, DeAngelis CD, Frizelle FA, Godlee F, Haug C, Hébert PC, Horton R. Towards more uniform conflicts disclosures. BMJ 2010;341:3-4. [Ref.ID 88795]
Drazen JM, Van Der Weyden MB, Sahni P, Rosenberg J, Marusic A, Laine C, Kotzin S, Horton R, Hébert PC, Haug C, Godlee F, Frizelle FA, De Leeuw PW, DeAngelis CD. Uniform format for disclosure of competing interests in ICMJE journals . JAMA 2010;303:75-6. [Ref.ID 87543]
20.Tiene citas relacionadas Cita con resumen
Godlee F, Clarke M. Why don't we have all the evidence on oseltamivir?. BMJ 2009;339:1321-2. [Ref.ID 87427]
Seleccionar todas
 1 a 20 de 52 siguiente >>